PDCD1 and neoplasm: Programmed death 1 (PD-1) ligand (PD-L1) (CD274) expression, tumor mutation burden (TMB), and microsatellite instability (MSI) status of tumor tissue are potential predictors of anti-PD-1 treatment response (Schreiber et al., 2011; Galon and Bruni, 2019).